Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in developed countries, with its incidence growing parallel to the epidemics of obesity and type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are becoming a cornerst...

Descripción completa

Detalles Bibliográficos
Autores principales: Bañares, Juan, Manzano-Nuñez, Ramiro, Prió, Alba, Rivera-Esteban, Jesús, Camps-Relats, Laura, Villarejo, Ana, Ruiz-Ortega, Lourdes, Pons, Mònica, Ciudin, Andreea, Salcedo, María Teresa, Vargas, Víctor, Genescà, Joan, Pericàs, Juan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449723/
https://www.ncbi.nlm.nih.gov/pubmed/36093073
http://dx.doi.org/10.3389/fendo.2022.945626

Ejemplares similares

Ejemplares similares